Therefore, if the mechanism in the PHD1–HIF pathway, responsible for the supposed tumor suppression via PHD1, were to be found, a novel target for individualized colon cancer therapy may become available for selected patients. The gene discussed is EGLN2; the disease is colonic neoplasm.